Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I

Journal of Nuclear Medicine

Volumn 41, Issue 7, 2000, Pages 1198-1202

  Cholewinski, Scott P ^a   Yoo, Kenny S ^a   Klieger, Peter S ^a   O'Mara, Robert E ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

131I diagnostic imaging; Radioiodine ablation; Thyroid stunning

Indexed keywords

IODINE 131;

ARTICLE; DIAGNOSTIC IMAGING; HUMAN; IODINE 131 UPTAKE TEST; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; THYROID CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0033940014     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Verby JE, Woolner LB, Nobrega FT, et al. Thyroid cancer in Olmsted County, 1935-1965. J Natl Cancer Inst. 1969;43:813-820.
2. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin. 1996;65:5-27.
3. Frazell EL, Foote FW Jr. Papillary cancer of the thyroid: a review of 25 years of experience. Cancer. 1958;11:895-922.
4. Rawson RW, Rail JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. Paper presented at: Annual Meeting of the American Goiter Association; May 26, 1951; Columbus, OH.
5. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid. 1994;4:49-5-4.
6. Park HM. Stunned thyroid after high-dose I-131 imaging. Clin Nucl Med. 1992;17:501-502.
7. Muratet JP, Daver A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med. 1998;39:1546-1550.
8. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med. 1998;25:242-246.
9. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin. 1998;37:30-32.
10. Reynolds JC, Robbins J. The changing role of radioiodine in the management of differentiated thyroid cancer. Semin Nucl Med. 1997;27:152-164.
11. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer: a quantitative radiation dosimetric approach -outcome and validation in 85 patients. J Nucl Med. 1992;33:1132-1136.
12. Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med. 1978;20:92-97.
13. Pacini F, Lippi F, Formica N, et al. Therapeutic doses of I-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-1891.
14. Waxman A, Ramanna L, Chapman N. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med. 1981;22:861-865.
15. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937-941.